Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jan Holmgren

Showing results (11-20 of 126) with videos related to

Pageof 13
Sort By:
The Indian Journal of Medical Research|March 19, 2011
Cholera toxin - a foe & a friendJoaquin Sanchez, Jan Holmgren
Future Microbiology|May 7, 2009
Urgent need of cholera vaccines in public health-control programsJohn Clemens, Jan Holmgren
FEMS Immunology and Medical Microbiology|May 4, 2005
CD4+CD25+ suppressor T cells regulate pathogen induced inflammation and diseaseSukanya Raghavan, Jan Holmgren
Current Opinion in Investigational Drugs (London, England : 2000)|March 27, 2004
CpG DNA as a potent inducer of mucosal immunity: implications for immunoprophylaxis and immunotherapy of mucosal infectionsAli M Harandi, Jan Holmgren
Microbial Pathogenesis|October 13, 2009
Vibrio cholerae O139 capsular polysaccharide confers complement resistance in the absence or presence of antibody yet presents a productive target for cell lysis: implications for detection of bactericidal antibodiesStephen R Attridge, Jan Holmgren
Vaccine|July 11, 2006
CpG oligodeoxynucleotides and mobilization of innate mucosal immunity: tasks and tacticsAli M Harandi, Jan Holmgren
Current Opinion in Immunology|May 15, 2012
Vaccines against mucosal infectionsJan Holmgren, Ann-Mari Svennerholm
Mucosal Immunology|January 12, 2023
Memorial for Nils LyckeWarren Strober, Jan Holmgren, Allan Mowat
Journal of Immunology (Baltimore, Md. : 1950)|January 18, 2012
B lymphocytes treated in vitro with antigen coupled to cholera toxin B subunit induce antigen-specific Foxp3(+) regulatory T cells and protect against experimental autoimmune encephalomyelitisJia-Bin Sun, Cecil Czerkinsky, Jan Holmgren
The Lancet. Infectious Diseases|May 9, 2022
Evaluating improved inactivated oral cholera vaccines for use in ending endemic cholera by 2030: opportunities and challengesJacqueline Deen, Jan Holmgren, John D Clemens
Pageof 13

Showing results (11-20 of 126) with videos related to

Sort By:
Pageof 13
The Indian Journal of Medical Research|March 19, 2011
Cholera toxin - a foe & a friendJoaquin Sanchez, Jan Holmgren
Future Microbiology|May 7, 2009
Urgent need of cholera vaccines in public health-control programsJohn Clemens, Jan Holmgren
FEMS Immunology and Medical Microbiology|May 4, 2005
CD4+CD25+ suppressor T cells regulate pathogen induced inflammation and diseaseSukanya Raghavan, Jan Holmgren
Current Opinion in Investigational Drugs (London, England : 2000)|March 27, 2004
CpG DNA as a potent inducer of mucosal immunity: implications for immunoprophylaxis and immunotherapy of mucosal infectionsAli M Harandi, Jan Holmgren
Microbial Pathogenesis|October 13, 2009
Vibrio cholerae O139 capsular polysaccharide confers complement resistance in the absence or presence of antibody yet presents a productive target for cell lysis: implications for detection of bactericidal antibodiesStephen R Attridge, Jan Holmgren
Vaccine|July 11, 2006
CpG oligodeoxynucleotides and mobilization of innate mucosal immunity: tasks and tacticsAli M Harandi, Jan Holmgren
Current Opinion in Immunology|May 15, 2012
Vaccines against mucosal infectionsJan Holmgren, Ann-Mari Svennerholm
Mucosal Immunology|January 12, 2023
Memorial for Nils LyckeWarren Strober, Jan Holmgren, Allan Mowat
Journal of Immunology (Baltimore, Md. : 1950)|January 18, 2012
B lymphocytes treated in vitro with antigen coupled to cholera toxin B subunit induce antigen-specific Foxp3(+) regulatory T cells and protect against experimental autoimmune encephalomyelitisJia-Bin Sun, Cecil Czerkinsky, Jan Holmgren
The Lancet. Infectious Diseases|May 9, 2022
Evaluating improved inactivated oral cholera vaccines for use in ending endemic cholera by 2030: opportunities and challengesJacqueline Deen, Jan Holmgren, John D Clemens
Pageof 13